When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ARQT - Arcutis commences study of JAK1 inhibitor on hand eczema
Arcutis Biotherapeutics Inc.
Enrollment is underway in a Phase 1/2b clinical trial evaluating Arcutis Biotherapeutics (ARQT-2.4%) ARQ-252 in adult patients with eczema (atopic dermatitis) on their hands.
More news on: Arcutis Biotherapeutics, Inc., Healthcare stocks news, Stocks on the move,